CD44 and systemic sclerosis: In addition, the low levels of sGPNMB released from these cells (pg/ml range) versus the dose needed (ng/ml range) for the anti-fibrotic effect might further reduce the anti-fibrotic effect of the sGPNMB-CD44 axis in SSc.